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ABSTRACT: The human antigen R (HuR) is an RNA-binding
protein known to modulate the expression of target mRNA
coding for proteins involved in inﬂammation, tumorigenesis,
and stress responses and is a valuable drug target. We previ-
ously found that dihydrotanshinone-I (DHTS, 1) prevents the
association of HuR with its RNA substrate, thus imparing its
function. Herein, inspired by DHTS structure, we designed
and synthesized an array of ortho-quinones (tanshinone mimics)
using a function-oriented synthetic approach. Among others,
compound 6a and 6n turned out to be more eﬀective than 1,
showing a nanomolar Ki and disrupting HuR binding to RNA
in cells. A combined approach of NMR titration and molecular dynamics (MD) simulations suggests that 6a stabilizes HuR in a
peculiar closed conformation, which is incompatible with RNA binding. Alpha screen and RNA-electrophoretic mobility shift
assays (REMSA) data on newly synthesized compounds allowed, for the ﬁrst time, the generation of structure activity rela-
tionships (SARs), thus providing a solid background for the generation of highly eﬀective HuR disruptors.
■ INTRODUCTION
The human antigen R (HuR), also known as HuA or ELAVL1,
is an ubiquitously expressed RNA binding protein that binds pref-
erentially to adenine- and uridine-rich elements (ARE) of target
coding and noncoding RNAs.1−3 HuR is primarily localized in
the nucleus, where it exerts post-transcriptional functions such
as splicing4,5 and alternative polyadenylation,6 although it shuttles
to the cytoplasm carrying the targeted RNA to be spatiotempo-
rally regulated in translation and stability.7 As a stress-response
protein, HuR modulates the expression of target mRNA
(containing AREs preferentially in their 3′UTR) coding for
proteins involved in inﬂammation,8 cell division,9 tumorigene-
sis,10,11 angiogenesis,12,13 metastasis,14 senescence,15 apoptosis,16,17
immune,18,19 or stress responses.20 The importance of HuR
in inﬂammation and cancer has encouraged the research for
inhibitors/modulators to interfere with its biological activity.21
Several compounds have been named as HuR disruptors
(i.e., molecules that can inhibit the HuR−RNA complex for-
mation).22−30 For a detailed description of the known inhibi-
tors and their properties, an exhaustive perspective has been
recently published.31 However, neither systematic structure−
activity relationships (SARs) studies, nor chemical synthesis of
novel families of HuR inhibitors have been reported so far.
From a structural point of view, rational design of HuR inhib-
itors is rather challenging due to the protein conformational
plasticity.32−34 Moreover, HuR switches between at least two
conformations upon binding/unbinding of its RNA substrate:
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an “open” (apo) conformation, which is characterized by almost
no contacts between its ﬁrst two RNA recognition motif (RRM)
domains, and a “closed” (holo) conformation, which is instead
characterized by a few inter-residue contacts between the RRM
domains.
Recently, as a result of a high throughput screening on a
set of anti-inﬂammatory agents, we identiﬁed 1 (Dihydrotan-
shinone-I, DHTS, Figure 1), a low-molecular-weight natural
product able to interact with HuR, thus aﬀecting its post-
transcriptional functions.27 Compound 1 is a major component
of extracts from Danshen (Salvia miltiorrhiza) used in tradi-
tional Chinese medicine as a treatment for inﬂammation,
cardiovascular, and cerebrovascular diseases.35 Our detailed
in vitro and in vivo characterization of 1 showed the HuR depen-
dency of its mechanism of action27 and its potency on cancer-
linked HuR−mRNA interactions.11 Naturally occurring tan-
shinones 2−4 (Figure 1) were tested as HuR inhibitors,
observing a preference for an aryl condensed (compounds 1,2)
vs saturated D rings (compounds 3,4).27
Structural complexity has long hindered the synthetic exploi-
tation of natural products as drug-oriented chemotypes. How-
ever, molecular editing through diverted total synthesis36 and
function-oriented synthesis (FOS)37 are synthetic paths that
help to transform a natural product to a simpler, equally active
synthetic analogue.38
We applied a FOS approach to 1, starting from the bicyclic
A−B scaﬀold 5 (Figure 2). It contains the o-quinone group
and a pyrrole A ring, to provide novel, 1-inspired, synthetic
tanshinone mimics bearing R1-R4 substitutions. Here the syn-
thesis of a small library of tanshinone mimics 6a−t, w, bearing
substitutions in positions 1, 3, 6, and 7, is reported. Tanshinone
mimics were tested for inhibition of HuR−RNA interactions
and SARs were established. The most potent HuR inhibitor 6a
(Figure 2) was further characterized in a panel of in vitro and
cellular assays and showed a direct KD of 4.5 μM to HuR. The
molecular interaction of 6a with HuR and with the HuR−
mRNA complex was also elucidated via a combined approach
of NMR and computational studies and grounded the path for
the next generation of HuR inhibitors.
■ RESULTS AND DISCUSSION
Synthesis. Retrosynthesis. A FOS-based approach to natu-
ral products analogues entails the design of an uncomplicated
synthetic strategy toward equally active, signiﬁcantly simpler
compounds. We built our strategy around a B ring-like ortho-
quinone and we opted for a substituted, N-sulfonylatedbicyclic
A−B scaﬀold 6 as a function-oriented replacement for the
tanshinone A−D ring system. The furan-pyrrole A ring switch
was meant to provide HuR inhibition-inspired novelty, as the
N-substituted indole MPT0B098 (7, Figure 2) is a negative
modulator of HuR.39 This compound bears a substituted
sulfonamide in position 1, which was introduced on our A ring
(scaﬀold 6) to increase potency and further diversify our
mimics from naturally occurring tanshinones.
We reasoned that a preliminary SAR around positions 1, 3, 6,
and 7 on scaﬀold 6 could be established by exploiting
N-sulfonylations (functionalization of N-1, −SO2R1), Suzuki
couplings (functionalization of C-3, -R2), radical CH functional-
izations40 and Michael additions (functionalization of C-7, -R3)
and Diels−Alder cycloadditions (functionalization of C-6 and
C-7, -cycloR3-R4, Figure 2).
As to synthetic targets 6 (R1, R2, R4≠ H, or R1 - R4≠ H,
Scheme 1), we envisaged that functionalization of C-6 and/or
C-7 could be carried out on 1,3-disubstituted indole-4,5-diones
6 (R3, R4 = H). Such compounds could be made by
O-demethylation and oxidation of 1,3-disubstituted 5-methox-
yindoles 9. Compounds 9 could be prepared by 3-bromination
of commercially available 5-methoxyindole 8, followed by
N-sulfonylation and Suzuki coupling (Scheme 1).
1-Alkyl/Arylsulfonyl-3-aryl Indole-4,5-Diones 6a−6j. The
retrosynthetic scheme leading to 1,3-disubstituted indole-4,5-
diones 6 (R1, R2≠ H, R3 = R4 = H, Figure 1) was validated by
synthesizing 1-phenylsulfonyl-3-phenyl indole-4,5-dione 6a
(Scheme 2). 5-Methoxyindole 8 was brominated in position
Figure 1. Naturally occurring tanshinones 1−4.
Figure 2. Tanshinone mimics as HuR inhibitors: core scaﬀold,
function-oriented synthesis, active analogues.
Scheme 1. Retrosynthetic Analysis to Tanshinone Mimics 6
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3 (step a, compound 10) and treated with phenylsulfonyl
chloride (step b). 3-Bromo phenylsulfonamide 11 was reacted
with phenyl boronic acid in a Suzuki coupling (step c) to
provide, after careful optimization of the experimental protocol,
1-phenylsulfonyl-3-phenyl-5-methoxyindole 9a. Demethylation
(step d, compound 12a) and oxidation with IBX41 (step e) led
to 1-phenylsulfonyl-3-phenyl indole-4,5-dione 6a (Scheme 2)
with an overall ≈35% yield.
3-Bromo phenylsulfonamide 11 was reacted with o- (R2 =
o-MePh, 9b) and p-substituted phenyl boronic acid (R2 =
p-NMe2Ph, 9c) (step c), and respectively converted to
1-phenylsulfonyl-3-o-methylphenyl indole-4,5-dione 6b and
1-phenylsulfonyl-3-p-dimethylaminophenyl indole-4,5-dione
6c (steps d,e, Scheme 2) as reported for 6a.
The synthesis of p-substituted (R2 = p-OMe, 9d) and
m-substituted (R2 = m-OMe, 9e) aryl ethers (Scheme 3) required
demethylation of the 5-methoxy group on 3-bromo phenyl-
sulfonamide 11 (step a) before Suzuki coupling (step b) and IBX
oxidation (step c, Scheme 3) to avoid undesired demethylation of
the 3-m- or p-methoxyphenyl group.
We attempted the synthesis of 1-alkylsulfonyl or 1-m/
p-substituted arylsulfonyl-3-phenyl indole-4,5-diones 6f−l by
replacing phenylsulfonyl chloride with alkyl- or m/p-arylsulfonyl
chlorides (Scheme 2). Unfortunately, the Suzuki coupling proto-
col optimized for the synthesis of 9a was not applicable as such
to other sulfonamides. Thus, we synthesized compounds
6f-i,k,l according to the longer, more eﬃcient strategy depicted
in Scheme 4.
1-Phenylsulfonyl-3-phenyl-5-methoxyindole 9a was desulfo-
nylated (step a, compound 14) and treated with aryl- (step b)
or alkylsulfonamides (step b′) to provide 1-m/p-substituted
arylsulfonyl- and 1-methylsulfonyl-3-phenyl-5-methoxy indoles
(respectively 9f−i and 9l) in good to excellent yields. 1-p-
Nitrophenylsulfonyl-3-phenyl-5-methoxyindole 9f was reduced
(step c, amine 9j) and acetylated to 1-p-acetamidophenylsul-
fonyl-3-phenyl-5-methoxyindole 9k (step d). Conversion of
aryl ethers 9f−i,k,l into 1-m/p-substituted arylsulfonyl- or
1-alkylsulfonyl-3-phenyl indole-4,5-diones 6f−i,k,l (steps e and f,
Scheme 4) was carried out as previously described for 6a.
1-Phenylsulfonyl-3-phenyl-7-thioaryl Indole-4,5-diones
6m−6o. The retrosynthetic scheme leading to 1,3,7-trisub-
stituted indole-4,5-diones 6 (R1, R2≠ H, R3 = S−Ar, R4 = H,
Figure 2) was validated by synthesizing 1-phenylsulfonyl-3-
phenyl-7-thiophenylindole-4,5-dione 6m (Scheme 5) via
Michael addition of substituted benzenethiols on o-quinones.41
Namely, 1-phenylsulfonyl-3-phenyl indole-4,5-dione 6a was
treated with thiophenol (step a), providing 1-phenylsulfonyl-3-
phenyl-7-thiophenylindole-4,5-dione 6m after oxidation of the
reduced form (step b, Scheme 5) in moderate yield after
Scheme 2. Synthesis of 1-Phenylsulfonyl-3-aryl Indole-4,5-
diones 6a−ca
aReagents and conditions: (a) Br2, DMF, rt, 24 h, 74%; (b) PhSO2Cl,
n-Bu4N
+HSO4
−, aqueous 50% KOH, CH2Cl2, rt, 3 h, 90%; (c) ary-
lboronic acid, Pd(PPh3)4, dry DME/EtOH 4/1, N2 atmosphere, rt, reﬂux,
8 h, 83−92%; (d) 1 M BBr3 in dry CH2Cl2, N2 atmosphere, −78 to 5 °C,
87−99%; (e) IBX, EtOAc (40 °C) or DMF (rt), 2 to 24 h, 87−96%.
Scheme 3. Synthesis of 1-Phenylsulfonyl-3-methoxyphenyl
Indole-4,5-diones 6d,ea
aReagents and conditions: (a) 1 M BBr3 in dry CH2Cl2, N2
atmosphere, −78 to 5 °C, 86%; (b) methoxyphenylboronic acid,
Pd(PPh3)4, dry DME/EtOH 4/1, N2 atmosphere, rt, reﬂux, 8 h,
79−85%; (c) IBX, DMF, rt, 6 to 48 h, 67−87%.
Scheme 4. Synthesis of 1-Alkyl/Arylsulfonyl-3-phenyl
Indole-4,5-diones 6f−i,k,la
aReagents and conditions: (a) aqueous 3 M NaOH, 2/1 MeOH/THF,
80 °C, 2 h, 98%; (b) R1SO2Cl, n-Bu4N
+HSO4
−, 50% KOH, CH2Cl2, rt,
3 h, 87−92%; (b′) NaH, mesyl chloride, dry DMF, N2 atmosphere,
0 °C to rt, 3 h, 59%; (c); SnCl2·2H2O, 1/1 THF/MeOH, 80 °C, 2 h,
95%; (d); Ac2O, pyridine, CH2Cl2, rt, 22 h, 82%; (e) 1 M BBr3 in dry
CH2Cl2, N2 atmosphere, −78 to 5 °C, 73−99%; (f) IBX, EtOAc (40 °C)
or DMF (rt), 2 to 24 h, 87−96%.
Scheme 5. Synthesis of 1-Phenylsulfonyl-3-phenyl-7-thioaryl
Indole-4,5-diones 6m−6oa
aReagents and conditions: (a) aryl thiol, DMF, 2−3 h, rt, 62−88%;
(b) IBX, DMF, 2 h, rt, 52−56%.
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extensive optimization. The optimized experimental protocol
was used with p-methoxybenzenethiol (6n) and p-carboxyme-
thylbenzenethiol (6o), observing moderate two step yields for
both quinones.
1-Phenylsulfonyl-3-phenyl-7-aryl Indole-4,5-diones 6p−6t.
The retrosynthetic scheme leading to 1,3,7-trisubstituted indole-
4,5-diones 6 (R1, R2, R3≠ H, R4 = H, Figure 1) was validated by
synthesizing 1-phenylsulfonyl-3,7-diphenylindole-4,5-dione 6p
(Scheme 6) via Mn(III)-mediated radical addition of boronic
acids.40,42 1-Phenylsulfonyl-3-phenyl indole-4,5-dione 6a was
treated with phenylboronic acid and Mn(OAc)3 (step a), provid-
ing 1-phenylsulfonyl-3,7-diphenylindole-4,5-dione 6p (Scheme 6).
The experimental protocol required extensive optimization,
and a moderate yield was ﬁnally obtained. The optimized experi-
mental protocol was then used with aryl- (6q−s) and alkylbo-
ronic acids (6t), adapting the reaction time to each substrate
(Scheme 5) and observing poor to moderate reaction yields.
Diels−Alder Cycloadducts 6u−6w. Validation of the retro-
synthetic scheme to 1,3,6,7-tetrasubstituted indole-4,5-diones 6
(R1, R2≠ H, cyclo R3R4, Figure 1) targeted 1-phenyl-3-
phenylsulfonyl-6-methylphenantro[1,2-b]pyrrole-10,11-dione 6v.
We envisaged a Diels−Alder cycloaddition between 1-phenyl-
sulfonyl-3-phenyl indole-4,5-dione 6a and 6-methyl-1-
vinylcyclohexene 15a, followed by DDQ dehydrogenation/
aromatization of tetrahydrocycloadduct 6u to aromatic 6v
(Scheme 7).43 Unfortunately, we could not obtain pure diene
15a in reasonable amounts following the published synthetic
procedure.43
Due to the inhibitory activity observed with bicyclic indole-
4,5-dione 6a and some of its congeners, a tetracyclic,
tanshinone-like core should not be necessarily needed to
prevent HuR−mRNA interactions. Thus, cycloadditions on
dienophile 6a were targeted to introduce potency-oriented
(additional interactions with the binding site on HuR) and/or
“druggability”-oriented substitutions on C-6 and C-7 (modu-
lation of selectivity, solubility, and lipophilicity, etc.).
Diels−Alder cycloaddition between 1,3-cyclohexadiene 15b
and dienophile 6a provided a mixture of desired ortho-quinone
6w and diphenol 16b (step a, Scheme 8). Oxidation (step b)
converted the mixture to pure 6w.
A more systematic eﬀort toward tanshinone-like 1,3,6,7-
tetrasubstituted indole-4,5-diones 6 (R1, R2≠ H, cyclo R3R4,
Figure 1) will be carried out, and reported in future.
Biochemical Characterization. Compounds 6a and 6n
Are More Eﬀective than 1 in Inhibiting the HuR−RNA Complex
Formation. Tanshinone mimics 6a−i, 6k−t, and 6w were evalu-
ated using a previously developed biochemical tool based on
Ampliﬁed Luminescent Proximity Homogenous Assay Alpha-
Screen technology.27,28 Recombinant His-tagged HuR (rHuR)
bound to nickel chelate acceptor beads was incubated with a
biotinylated single-strand AU-rich RNA probe (Bi−AU),
recognized by streptavidin-coated donor beads. When rHuR
binds to the Bi−AU, the beads are brought into proximity and a
ﬂuorescent signal can be detected. We evaluated the ability of
tanshinone mimics to inhibit the rHuR−Bi−AU complex forma-
tion in saturation binding conditions. Knowing that the KD value
for the rHuR−Bi−AU interaction is 2.5 nM,27 we ﬁtted on
AlphaScreen saturation curves the Ki values, quantifying the
inhibitory eﬃciency of tested compounds from high to low
nanomolar range (Table 1). Among tanshinone mimics show-
ing Ki with a percentage of inhibition >50%, compounds 6a
(Ki = 12.8 nM) and 6n (Ki = 15 nM) were more eﬀective
than 1, whereas compounds 6h, 6k, 6l, 6r, and 6s showed similar
activity (Figure 3 and Table 1). Consistently with previous
data,27 Ki value of our compounds changes according to the
host in which the recombinant protein is produced (Supporting
Figure 1).
Tanshinone mimics 6b, 6f, 6m, and 6o resulted interfered
with the emitted ﬂuorescence in AlphaScreen;44,45 thus, we pro-
ceeded with a second independent, orthogonal assay protocol
for these and a few other tanshinone mimics (Figure 4 and
Supporting Figures 2 and 3). We evaluated their inhibitory
activity via a non denaturing and non-cross-linked REMSA.27,28
After we mixed at least 10-fold excess of rHuR with 75 fmol
of 5′-DY681-labeled AU-rich RNA probe (DY681-AU) or with
25 nM of FAM-RNA probe, we observed the formation of the
higher, oligomeric molecular weight complex between protein
and RNA. The concomitant addition of active tanshinone
mimics (5 μM concentration) caused a reduction of the shifted
RNA probe, allowing qualitative estimation of their inhibitory
ability toward the Bi−AU ligand at equilibrium. We noticed a
Scheme 6. Synthesis of 1-Phenylsulfonyl-3-phenyl-7-aryl
Indole-4,5-diones 6p−6ta
aReagents and conditions: (a) boronic acid, Mn(OAc)3, 1,2-dichloro-
ethane, 80 °C, 30 to 150 min, 14−36%.
Scheme 7. Attempted Synthesis of 6,7,8,9-Tetrahydro-1-
phenyl-3-phenylsulfonyl-phenanthro[1,2-b]indole-10,11-
dione 6v
Scheme 8. Synthesis of Cycloadduct 6wa
aReagents and conditions: (a) cat. dry ZnCl2, dry CH2Cl2, Ar atmo-
sphere, 0 °C, 5 min, 88%; (b) CAN, 2/1 MeCN/H2O, 0 °C, 10 min,
quantitative.
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concordance between the two biochemical assays for com-
pounds 6a, 6c, 6k, 6n, 6p−6t, and 6w. Tanshinone mimics 6b,
6f, 6m, and 6o were therefore classiﬁed as inhibitors endowed
with intermediate potency (Figure 4). Compound 6a was tested
for binding to RNA probe via REMSA and circular dichroism
(CD) (Supporting Figure 4A,B), showing no interference with
the ﬂuorescent probe and no change of the RNA conformation,
thus suggesting the absence of an interaction with RNA.
Table 1. Abilities of Tanshinone Mimics To Inhibit the
rHuR−Bi−AU Complex Formationa
aNotes: 1Concentration (nM) leading to half-maximal inhibition of
rHuR−Bi−AU complex. *Interfering with the ﬂuorescence spectra of
excitation−emission of donor and acceptor beads (histidine (nickel)
chelate detection kit).
Figure 3. Ki calculation by Alpha screen assessing speciﬁc binding of
His-tagged HuR and the AU-rich biotinylated RNA. Ki were calculated
with respect to a KD of 2.5 nM for the rHuR−Bi−AU interaction
and normalized to control (DMSO). Fitting curves show nonlinear
regression ﬁts of the data according to a 1-site binding model in
GraphPad Prism. Plotted bars are mean ± SD of two independent
experiments.
Figure 4. REMSA characterization of selected tanshinone mimics.
REMSA assay performed with at least 10-fold excess of recombinant
HuR incubated for 30 min with 75 fmol of 5′-DY681-labeled RNA
probe. Incubation with RNA probe only (−), with rHuR, RNA probe
and DMSO (+) used as positive control of the binding, and incubation
with tanshinone mimics 6 (5 μM).
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Tanshinone Mimic 6a Directly Binds to HuR Protein and
Modulates Its Binding with Intracellular Target mRNAs.
Compound 6a was selected among the most potent tanshinone
mimics for further evaluation. It showed a similar mechanism to
1 in interacting with the truncated form of HuR comprising the
ﬁrst two RRM domains (RRM1-RRM2) but not with the third
domain (RRM3) and not with the RNA probe (Supporting
Figure 4 and 5).
Dynamic mass redistribution (DMR) analysis46 revealed, in a
label-free format, a direct protein:6a interaction at the equi-
librium (Figure 5). Full-length rHuR was immobilized onto the
surface of label-free microplates by amine-coupling chemistry.
Diﬀerent amounts of 6a (0.03−100 μM) were added to the
wells and the mass of molecular complexes was detected after
30 min incubation. Dose-dependent binding of 6a to rHuR
was observed in the 0.3−10 μM range, suﬃcient to obtain
saturation. The estimated aﬃnity constant (KD) was ≈4.5 μM.
The same experiment was performed with 1, but it was impos-
sible to evaluate the KD due to its poor solubility.
27
We then determined if 6a was interfering on HuR−RNA
binding in MCF7 cells. We performed an RNA immunopre-
cipitation (RIP) assay47 on MCF7 extracts testing three vali-
dated HuR transcripts. We clearly observed a subsequent decrease
of the relative number of mRNA copies and a decreased expres-
sion level of such mRNAs (ERBB2, CTNNB1, VEGF) but not
of non target genes (RPLP0, HPRT1) (Figure 6A,B). There-
fore, compound 6a directly binds to HuR both in vitro and in
cellular context, in a region contained between the ﬁrst two
RRM domains.
NMR and Molecular Modeling. Tanshinone Mimic 6a
Blocks HuR in a “Closed” Conformation. The 2D 1H−15N
HSQC spectrum of RRM1-RRM2 domains showed well-
dispersed signals in accordance with a folded protein structure,
whose residues, including those of the linker region, have been
previously assigned.29 The resonances of residues forming the
RRM1 domain are almost the same in the isolated domain48
and in the RRM1-RRM2 construct. The large superimposition
of the signals in the isolated RRM1 and in the tandem domains
is in agreement with the relaxation data that show as the two
domains move independently in solution in the absence of
RNA.29 In line with the previously reported crystal structures of
HuR, each domain in the RRM1-RRM2 construct is constituted
by two α-helices and four β-strands.49
The molecular interaction of 6a with RRM1-RRM2 tandem
domains of HuR was evaluated through solution NMR.50 Com-
pound 6a shows improved solubility with respect to 1.29 Its
eﬀects on the protein are appreciable in the 2D 1H−15N HSQC
in the presence of 0.6 equiv of the ligand, whereas with 1 compa-
rable eﬀects were observed after the addition of 4 equiv. As also
reported for 1,29 a generalized decrease in signal intensity was
observed for the protein resonances, with few residues (Thr20,
Leu22, Val66, Ser94, Tyr95, Ile103, Asn107, Leu108, Tyr109,
Ile133, Val137, Leu138, Val139, Ser146) experiencing a stron-
ger eﬀect (Figure 7). Tanshinone mimic 6a and 1 interact with
the protein in the same region, i.e. the β-platform of both domains.
In particular, eight amino acids (Thr20, Ser94, Tyr95, Asn107,
Leu108, Ile133, Val137, Leu138) experience a decrease in
signal intensity with both ligands.
The generalized decrease of signal intensity, together with
the distribution of aﬀected residues over the large surfaces of
the β-platform in each domain suggests an alteration of the
equilibrium between “closed” and “open” conformations upon
ligand binding. Speciﬁcally, the decrease of signal intensity was
consistent with a mechanism where compound 6a stabilizes a
“closed” conformation of HuR. Collectively, NMR analysis
Figure 5. Compound 6a binds to recombinant HuR. Diﬀerent con-
centrations of 6a were added to label-free microplate wells on which
aliquots of full-length protein had previously been immobilized. Mea-
surements were performed before (baseline, protein-coated wells) and
after (ﬁnal) adding the compound. The response (pm) was obtained
subtracting the baseline output from the ﬁnal output signals. The
output signal for each well was obtained by subtracting the signal of
the protein-coated reference area from the signal of uncoated area. The
data (red dots) were ﬁtted (black line) to a sigmoidal function using
a 4-parameter logistic (4PL) nonlinear regression model: R2 = 0.944;
p = 0.009.
Figure 6. RIP and quantitative real-time PCR (qRT-PCR). (A) RIP
was performed in MCF7 cells, lysed after 6 h treatment with DMSO
(CTRL), 1 (1 μM) or 6a (5 μM). HuR antibody (IP) and an IgG
isotype (IgG) were used for RNA precipitation. Changes in the
mRNAs bound to HuR in the control or treatment condition were
assessed by qRT PCR and compared with the ones obtained with IgG
precipitation, used as negative control. The relative values (Fold
enrichment) were normalized to IgG, considering the value of the
housekeeping gene RPLP0. (B) MCF7 were treated with 6a (5 μM)
for 6 h to evaluate changes in total RNA levels. Expression level of
ERBB2, CTNNB1, VEGF, RPLP0, and HPRT1 were measured by
qRT-PCR and normalized to RNA18s. Data are presented as mean ± SD
of a biological triplicate (*p < 0.05 and **p < 0.01 versus CTRL).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01176
J. Med. Chem. XXXX, XXX, XXX−XXX
F
indicates that 1 and 6a bind the HuR protein approximately in
the same region, producing similar eﬀects on protein dynamics.
However, it is interesting to note that one residue (Ile103) of
the interdomain linker (hereafter referred to as “hinge” loop) is
sensitive to 6a and not to 1. This experimental evidence would
suggest for 6a a binding site in a more close proximity of the
hinge loop, with respect to 1. To better explore this possibility,
a molecular modeling study was performed.
To this purpose, a combined approach of docking cal-
culations and extended molecular dynamics (MD) simulations
was applied. Speciﬁcally, we ﬁrst attempted a “blind” docking to
the entire HuR surface, using two diﬀerent docking software to
better sample the binding space (AutoDock4.2 and Glide 6.5).
Most of the highest-score poses of 6a suggested by AutoDock
were located within the RNA binding cleft (residues 18 to 95 of
RRM1 and 107 to 185 of RRM2) and in proximity of the
“hinge” loop. On the other hand, docking results with Glide
converged toward one solution, which was diﬀerent from those
predicted by Autodock, though it was placed in proximity of the
“hinge” loop as well. Therefore, albeit these results seem to
indicate the region surrounding the “hinge” loop as the most
likely binding region for 6a, docking failed to unequivocally
pinpoint one privileged binding mode, likely owing to omission
of full receptor ﬂexibility from the state-of-the-art docking soft-
ware. To account for the missing receptor ﬂexibility, we carried
out multiple extended MD simulations on a reasonable number
of 6a binding modes, for a total simulation time of 6 μs, and
assessed their relative stability. Speciﬁcally, we opted for the
binding pose predicted by Glide (Figure 8A) and the three best
ranked and most diverse poses (in terms of root-mean-square
deviation (RMSD) predicted by AutoDock) (Figure 8B,C,D).
In all four cases, 6a drifted away from its starting docking
position and explored a signiﬁcant portion of the HuR surface,
Figure 7. Compound 6a stabilized recombinant HuR in a “closed”
conformation. (A) Graphical representation of the intensity changes of
RRM1-RRM2 HuR protein per residues in the presence of 0.6 equiv
of 6a. The residues exhibiting the highest decreases in signal intensities
are colored in red. The secondary structures of the domains are
reported on the graph. (B) Surface representation of the closed
(PDB ID: 4ED5) conformation of HuR. The residues exhibiting the
largest decrease in signal intensities in the presence of 0.6 equiv of 6a
are shown in red.
Figure 8. (A−D) 6a exploration of the HuR RNA-binding pocket for each simulated pose. HuR is shown as purple cartoons, while the 6a center of
mass is shown as spheres colored according to the simulation time. (E,F) Global view of the HuR−6a complexes in each ﬁnal MD simulation pose.
Note how the binding of 6a (green sticks) to HuR and the further closure of the mRNA binding cleft, as compared to the mRNA-bound
conformation (yellow), prevent the accommodation of the mRNA strand (red ribbons). In both groups of pictures, panels related to the pose
predicted by Glide and the three highest score poses predicted by Autodock are arranged from left to right, respectively.
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as can be observed by following the movement of the center of
mass of 6a (Figure 8A−D), its RMSD vs time (Supporting
Figure 6A) or its distance from the center of mass of the two
RRM domains (Supporting Figure 6B). After about 1 μs, each
starting docking pose got stabilized and evolved to diﬀerent
ﬁnal binding modes (Figure 8E-H) which remain individually
stable for almost 500 ns. Speciﬁcally, out of the four ﬁnal
binding poses, one was located outside the RNA binding cleft
(the Glide predicted binding pose, Figure 8E) while the other
three were located within the latter pocket, in correspondence
or in close proximity of the “hinge” loop. In these ﬁnal poses 6a
stabilizes HuR in a conformational state that is structurally
incompatible with RNA binding. In fact, in each case the two
RRM domains were found to be more in contact with each other
than in the HuR−RNA complex crystal structure (Figure 8E−H).
Accordingly, we observed an increase in both the number of
non-native interdomain contacts and the amount of surface
area “buried” between the two RRM domains (see respectively
Supporting Figure 7A and 7B). These results indicate that
binding of 6a to HuR is correlated with a closure of the RNA
binding cleft and, consequently, with an overall decrease in the
amount of interdomain space accessible for RNA binding.
Nevertheless, among the four poses issuing from our mod-
eling approach, the one depicted in Figure 8F and more in detail
in Figure 9 seems to be more in agreement with both the NMR
data and the SARs reported here. Speciﬁcally, 6a was found
between the RRM1 beta sheets (β1, β2, β3), the N-terminal
part of the RRM2 α2 helix and the “hinge” loop. In this binding
arrangement (Figure 9), the phenyl ring in R1 is accommodated
in a narrow, laterally open, hydrophobic pocket, shaped by
Ile103, Ser99, Lys104 and Lys156 residues, with which it estab-
lishes several CH-π interactions. Notably, one sulfonyloxygens
establishes a water-bridged H-bond with the backbone CO
of Ala96, while the phenyl ring in R2, forms a cation-π inter-
action with Lys156 and several CH-π interactions with the CH2
groups of Ser48, Lys50, Asn67 and Lys156. The indole-4,
5-dione moiety is inserted in a solvent exposed pocket, where it
establishes CH-π interactions with Ala96, Lys156, Ser158 and, a
π-stacking interaction with Phe65. In this regard, the quinone-
oxygens, which point to the solvent exposed part of the pocket,
likely play a crucial role in strengthening the π-stacking inter-
action with Phe65.
As compared to the other poses, in the above-described bind-
ing mode, 6a is in close proximity with a larger number of HuR
residues exhibiting the highest decreases in NMR signal inten-
sity (Figure 7A). Precisely, these residues are Leu22, Val66, and
Ile103. Notably, NMR pinpointed I103 in the “hinge” loop as a
residue sensitive to binding of 6a but not of 1, which is known
to stabilize HuR in a closed form without stably interacting with
the “hinge” loop.29 As compared to the other binding poses,
which are located either outside the RNA binding cleft or in
more solvent exposed regions, this binding mode (Figure 9)
would be in line also with SARs studies. It would explain why
substitutions on the phenyl ring in R1 (6f, 6g, 6h, 6i, 6k, 6l),
though still causing a drop in the activity, are generally better
tolerated than those on the phenyl ring in R2 (6b, 6c, 6d, 6e).
In fact, thanks to the additional lateral space in the pocket
hosting the phenyl ring in R1, this ring could slightly rotate
around the S−N bond so as to allow the attachment of various
substituents, even large ones as in the case of 6k. This would
not be possible at position R2, owing to potential steric clashes
with residues shaping the pocket where it is hosted. This
binding mode would also explain why the addition of electron-
drawing substituents on the phenyl group in R1 (6f, 6g, 6h, 6i),
particularly at the meta position (6g, 6i), also causes a drop in
the activity. In fact, these substitutions would likely weaken
the aforementioned water-bridged H-bond with Arg97. Finally,
SARs indicate that the addition of rigid and bulky substituents
at position 6−7 (see 6w) or 7 (6p, 6q, 6r, 6s, 6t) of the bicyclic
scaﬀold (B ring) is also generally detrimental to binding. Steric
clashes with the adjacent sulfonamidic group are very likely to
arise as a result of their introduction, which would force a rota-
tion around the S−N bond. That, according to our model,
would in turn lead to a rupture of the water-bridged H-bond
with Ala96 and of the hydrophobic interactions of the phenyl
ring in R1. In the case of 6q, but especially of 6r and 6s, the
presence of a H-bond donor at position 7 may partially com-
pensate for these detrimental eﬀects through the potential
formation of a H-bond with the near Arg97 side chain. The
only exception to this trend is represented by 6n, where the
presence of a sulfur atom directly linked to the scaﬀold likely
increases the rotational ﬂexibility and makes the addition of a
bulky group well tolerated.
In conclusion, our NMR and molecular modeling data pro-
vide useful insights into the binding mode and mechanism of
action of this family of compounds, suggesting that they most
likely bind HuR at the “hinge” region between the two RRM
domains and stabilize HuR in a peculiar closed conformation,
which is incompatible with RNA binding.
Biological Activity in Cancer Cell Lines. Selected Tan-
shinone Mimics Show Micromolar Cytotoxicity in Cancer Cells.
We previously reported that the anticancer eﬀects of 1 are
inﬂuenced by HuR dosage, demonstrating that HuR is func-
tionally connected with the intracellular eﬀects of this pleio-
tropic natural product.29 Similarly to 1, the localization of HuR
did not change during treatment with 6a or other tanshinone
mimics, suggesting that inhibition of HuR is connected with its
binding performances and not with its subcellular localization
(Figure 10).
We evaluated the cytotoxic eﬀects of tanshinone mimics. Com-
pounds 6a and 6n aﬀected the viability of cells when treated for
72 h, together with 6b, 6m, 6k, 6l and 6t at higher dosages
(Figure 11). They were tested on breast cancer cell lines MCF7
and MDA-MB-231, and on pancreatic ductal adenocarcinoma
cell line PANC-1. Tanshinone mimics were generally less eﬀec-
Figure 9. Most likely binding mode of 6a (green sticks) to HuR
(purple cartoons), as issuing from a representative structure of the last
500 ns of the MD simulation. HuR residues involved in binding
interactions with 6a are displayed as sticks.
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tive than 1 on cell viability (Figure 11, Supporting Table S1),
with an IC50 in the medium μM range (spanning from 20 to
50 μM for compounds 6a, 6b, 6n, and 6m, with PANC-1 being
the most sensitive cell line to the tested compounds). An IC50
value was achieved for 6a, 6b, 6n, 6m compounds (Figure 11).
Additionally, tanshinone mimic 6a could block the migration
of PANC-1 and MDA-MB-231 cells (Figure 12 and Supporting
Figure 8). Previously identiﬁed HuR disruptors show cytotoxic
activity in cancer cell lines and in xenograft models. MS-444
induced cell death in colon cancer cells xenografted in nude
mice,51 as did coumarin analogues in colon cancer cells in vitro.23
Additionally, MS-444 chemo-prevented the development of
intestinal tumors in APCmin mice, a model of familial adeno-
matosis polyposis, but it was detrimental in the context of chem-
ically induced inﬂammatory bowel disease (IBD). In this case,
MS-444 favored azoxymethane/dextran sodium sulfate (AOM/
DSS) tumorigenesis, size and invasiveness, therefore suggesting
a careful evaluation of the utilization of HuR disruptors in the
IBD settings.52 Tanshinone mimics 6a, 6b, 6m, 6n, 6k, 6l, and
6t showed moderate IC50 in cancer cell lines, that was com-
parable to MS-444 (5 to 15 μM in colon cancer cell lines)51
and coumarin analogues (50 to 75 μM eﬀective doses in colon
cancer cell lines).23 Therefore, tanshinone mimics do not aﬀect
HuR mobility directly and are endowed with interesting anti-
tumor properties.
■ CONCLUSIONS
In our previous report, as a result of a high throughput screening
on a set of anti-inﬂammatory agents, we identiﬁed 1, a low-
molecular-weight compound able to interact with HuR, thus
aﬀecting its post-trascriptional functions and contributing to its
cytotoxic properties.27 Very recently, we characterized its
mechanism of action through a multidisciplinary strategy.29
Here, inspired by 1 structure, we designed and synthesized an
array of ortho-quinones (tanshinone mimics). They are the ﬁrst
family of HuR disruptors, through which the SARs reported
here elucidate the steric/electrostatic requirements of a HuR
binding site. In this regard, two complementary techniques,
Alpha-Screen and REMSA, were used to quantify the inhibitory
activity of tanshinone mimics 6a−t. Among them, compounds 6a
and 6n turned out to be more eﬀective than 1 in HuR binding,
showing a Ki of 12.8 and 15 nM respectively. In addition, 6a is
the only molecule, to our knowledge, for which a direct KD
against HuR can be measured through DMR (KD ≈ 4.5 μM).
A combined approach of in vitro studies, NMR titration and MD
simulations clariﬁed the mechanism of action of compound 6a
that is to stabilize HuR in a peculiar closed conformation, which
is incompatible with RNA binding.
From a biological point of view compound 1 inhibited via-
bility and migration of breast cancer cell lines and induced cell
death in colon cancer cells xenografted in nude mice in a HuR
dependent manner,29 although its pleiotropic eﬀects contribute
to its activity. The diminished cytotoxicity of tanshinone mimics
compared to 1 could be ascribed to the reported multipharma-
cological eﬀects of the latter,53 or to limited bioavalability of
tanshinone mimics. Nevertheless, our ﬁrst generation tanshi-
none mimics are a valuable starting point to generate a more
potent, in vivo active set of anticancer compounds. Our current
eﬀorts aim to further expanding our SARs, and to improve the
eﬃcacy of tanshinone mimics on HuR modulation in cells through
the introduction of solubilizing moieties in position 1 and 7.
■ EXPERIMENTAL SECTION
Chemistry. Purity measurements were carried out by HPLC-MS,
using NMR data to corroborate our ﬁndings. All our ﬁnal compounds
resulted to be ≥95% pure.
General Procedures. 1H NMR spectra were recorded on a Bruker
Avance 400 MHz instrument in CDCl3, CD3OD, or D2O as solvent
at 400 MHz. 13C NMR spectra were recorded in CDCl3, CD3OD,
or D2O as solvent at 101 MHz. Coupling constants are given in Hertz
and are rounded to the nearest 0.1 Hz. LC−MS data were collected
with a Waters Acquity Ultra performance LC equipped with an
Acquity UPLC HSS T3 column (2.1 mm × 50 mm, 1.8 μm) and a SQD
detector. Puriﬁcations were carried out either by ﬂash chromatography
on silica gel (particle size 60 μm, 230−400 mesh), on Kieselgel, or by
Biotage ﬂash chromatography [Biotage columns Si-25-M (150 × 25 mm;
silica gel (40−63 μm), ﬂow rate 25 mL/min)], or by Biotage C18
reverse phase chromatography [Biotage column C18HS (150 × 25 mm;
KP-C18−HS (35−70 μm), ﬂow rate 25 mL/min)]. Final compounds
6a−i, 6k−p, 6s were puriﬁed by C18 reverse phase semipreparative
HPLC using a Waters X-Bridge column (19 mm × 15.0 cm, 5 μm).
Melting points were determined with a Stuart Scientiﬁc SMP3 melting
point apparatus. Solvents were distilled and dried according to stan-
dard procedures, and reactions requiring anhydrous conditions were
performed under nitrogen or argon atmosphere.
1-Phenylsulfonyl-3-phenyl-4,5-dioxoindole (6a). IBX40 (548 mg,
1.96 mmol, 1.2 equiv) was added to a solution of 1-phenylsulfonyl-3-
phenyl-5-hydroxy indole 12a (570 mg, 1.63 mmol, 1 equiv) in EtOAc
(8 mL, ≈0.17 M concentration), under vigorous stirring at room tem-
perature. The reaction was monitored by TLC (eluants: n-Hexane/
EtOAc 6/4). After 24 h, the reaction was ﬁltered on Celite. After the
Figure 10. Representative immunoﬂuorescence showing unchanged
subcellular localization of HuR after 6a treatment. HuR (red) or nuclei
(blue, DAPI) after staining in MCF7 cells treated for 3 h with DMSO
(CTRL) or 2.5 μM of actinomycin D (ActD)19 or 10 μM 6a. Plotted
in the graph are the ratio of HuR ﬂuorescent signal between nucleus
and cytoplasm (N/C). The image plate reader Operetta was used for
image acquisition (40× high NA objective) and evaluation by selecting
13 ﬁelds/well. The ratio N/C represents the mean ± SD of single cells
for every well (***p < 0.001).
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solvent was concentrated, the crude (930 mg, purple solid) was puriﬁed
by ﬂash chromatography on silica gel (eluents: n-Hexane/EtOAc 6/4).
Pure compound 6a (515 mg, 1.42 mmol, 87% yield, ≥ 95% purity)
was obtained as a dark red solid, mp 140 °C (dec.). 1H NMR (400 MHz,
acetone d6): δ(ppm) 8.25−8.23 (m, 2H, o-ArSO2), 8.07 (d, 1H, J =
10.5 Hz, H7), 7.87 (tt, 1H, J = 7.5 Hz, J = 1.2 Hz, p-ArSO 2), 7.78−7.74
(m, 3H, H2, m-ArSO2), 7.68−7.65 (m, 2H, o-Ar), 7.40−7.33 (m, 3H,
p-Ar, m-Ar), 6.21 (d, 1H, J = 10.5 Hz, H6).13C NMR (75.4 MHz,
acetone d6): δ(ppm) 182.3, 174.8, 138.5, 137.9, 136.5, 132.1, 131.5,
131.3, 130.5, 129.6, 129.1, 128.9, 128.5, 127.1. MS (ESI+): m/z 748.9
[2M+Na+]. Calculated MS, C20H 13NO4S: 363.06.
1-Alkyl/arylsulfonyl-3-phenyl-4,5-dioxoindoles, General Oxida-
tion Procedure A (6a, 6f−h, 6l). IBX40 (1.2 equiv) was added to a solu-
tion of 5-hydroxy indoles (1 equiv) in EtOAc (≈0.17 M concentration),
under vigorous stirring at room temperature. The reaction was moni-
tored by TLC. When the reaction was completed (between 7 and 34 h),
the mixture was ﬁltered on Celite. After concentration of the solvent, the
crude was puriﬁed by ﬂash chromatography on silica gel, aﬀording pure
1-arylsulfonyl-3-aryl-4,5-dioxo indoles as amorphous solids.
1-Arylsulfonyl-3-aryl-4,5-dioxoindoles, General Oxidation
Procedure B (6b−e, 6i, 6k). IBX40 (1.2 equiv) was added to a solu-
tion of 5-hydroxy indoles (1 equiv) in DMF (≈0.17 M concentration),
at room temperature and under vigorous stirring. The reaction was
monitored by TLC. When the reaction was completed (between 2 and
48 h), the mixture was diluted with water (20 volumes). The aqueous
phase was extracted with EtOAc (10 volumes, until colorless). The
collected organic layers were washed once with brine (20 volumes),
dried with anhydrous Na2SO4, and ﬁltered. The solvent was removed
Figure 11. Cell viability of tanshinone mimics, assessed after 72 h of treatment with the indicated compounds (0−50 μM). Plotted bars are mean ± SD
of a biological duplicate, normalized to control (DMSO). Relative IC50 and R
2 were calculated by nonlinear regression curve ﬁtting.
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under reduced pressure, and the resulting crude was puriﬁed by ﬂash
chromatography on silica gel, aﬀording pure 1-arylsulfonyl-3-aryl-4,5-
dioxo indoles as amorphous solids.
1-Phenylsulfonyl-3-phenyl-7-thiophenyl-4,5-dioxoindole
(6m). The title compound (30.2 mg, 45% yield over 2 steps, ≥
95% purity, mp 136 °C (dec.), purple solid) was prepared from
1-(phenylsulfonyl)-3-phenyl-4,5-dioxo indole 6a (55 mg, 0.15 mmol,
1.0 equiv) andtiophenol (18.2 μL, 0.178 mmol, 1.18 equiv) in DMF
(0.65 mL), following the general procedure for Michael reaction (2.5 h)
and IBX oxidation. 1H NMR (400 MHz, acetone-d6): δ(ppm)
7.89−7.63 (m, 12H, Ar), 7.59 (s, 1H, H2), 7.42−7.31 (m, 3H, Ar), 6.91
(s, 1H, H6). 13C NMR (100 MHz, acetone-d6): δ(ppm) 177.2, 173.6,
140.3, 138.1, 137.2, 135.7, 135.6, 131.2, 130.5, 130.4, 129.1, 129.0, 128.5,
128.1, 128.0, 127.3, 122.3, 120.9, 119.5. MS (ESI+): m/z 494.32
[M+Na+]. Calculated MS, C26H17NO4S2:471.06.
1-Phenylsulfonyl-3-phenyl-7-thioaryl-4,5-dioxoindoles,
General Procedure for Michael Reaction (6m−o). A substituted
thiophenol (1.18 equiv) was added to a solution of 1-(phenylsulfonyl)-
3-phenyl-4,5-dioxo indole 6a (1.0 equiv) in DMF (0.23M). The solu-
tion was stirred at room temperature for 2−3 h, then water (1 volume)
was added. The mixture was extracted with EtOAc (four times,
4 volumes), and the collected organic phases were dried over sodium sul-
fate, ﬁltered, and evaporated under reduced pressure. The crude was
puriﬁed by reverse phase chromatography (eluents: A CH3CN, B water,
from 0% A to 100% A), aﬀording the ortho-bisphenol (62%−88%).
IBX (0.5−2 equiv) was then added to the ortho-bisphenol (1eq) in
DMF (0.2 M) under stirring at rt. After reaction completion (2 h), water
was added (1 volume), and the mixture was extracted with EtOAc
(four times, 2 volumes). The collected organic phases were dried
over sodium sulfate, ﬁltered, and evaporated under reduced pressure.
The crude residue was puriﬁed by reverse phase chromatography
(eluents: A CH3CN, B H2O, from 0% A to 100% A) aﬀording pure
1-(phenylsulfonyl)-3-phenyl-7-thioaryl-4,5-dioxo indoles as amorphous
solids.
1-Phenylsulfonyl-3,7-diphenyl-4,5-dioxoindole (6p). The title
compound (32 mg, 0.072 mmol, purple solid, 34% yield considering
the recovery of 28 mg of unreacted 6a) was obtained from
1-(phenylsulfonyl)-3-phenyl-4,5-dioxo indole 6a (105 mg, 0.289 mmol,
1.0 equiv) and phenylboronic acid (55 mg, 0.452 mmol, 1.5 equiv) in
dry DCE (3 mL, ≈0.09 M), following the general procedure for
Mn(III)-mediated radical addition. 1H NMR (400 MHz, DMSO d6):
δ(ppm) 8.27 (2H, d, J = 7.7 Hz, o-Hs of PhSO2), 7.96 (1H, s, H2),
7.89−7.83 (2H, m, H6, p-H of PhSO2), 7.76 (2H, t, J = 7.7 Hz, m-Hs
of PhSO2), 7.72−7.76 (2H, m, o-Hs of 3-Ph), 7.50−7.36 (8H, m, m-
and p-Hs of 3-Ph, all Hs of 7-Ph). 13C NMR (75.4 MHz, DMSO d6):
δ(ppm) 179.5, 173.4, 137.0, 136.8, 136.0, 134.9, 130.9, 130.6, 128.7,
128.3, 128.1, 127.6, 125.0, 123.8, 121.3. MS (ESI+): m/z 440.21
[M+H+]. Calculated MS, C26H17NO4S: 439.09.
1-Phenylsulfonyl-3-phenyl-7-alkyl/aryl-4,5-dioxoindoles,
General Procedure for Mn(III)-Mediated Radical Addition (6p−t).
1-(Phenylsulfonyl)-3-phenyl-4,5-dioxo indole 6a (1.0 equiv) and a
boronic acid (1.5 equiv) were dissolved in dry dichloroethane (DCE,
≈0.09 M in 6a). The solution was stirred for 2 min and then Mn(OAc)3.
2H2O (3 equiv) was added. The mixture was kept under nitrogen
atmosphere, stirred at 80 °C until reaction completion (monitoring by
TLC, eluents: n-Hexane/EtOAc 7/3), and cooled at room temper-
ature. Then, CH2Cl2 (2 volumes) and saturated aqueous NaHCO3
(2 volumes) were added. The aqueous layer was extracted with CH2Cl2
(2 volumes, two times). The collected organic phases were washed with
brine (8 volumes, two times), dried over sodium sulfate, ﬁltered and
evaporated under reduced pressure to give a crude solid. The crude
was puriﬁed by ﬂash chromatography (eluents: n-Hexane/EtOAc 7/3).
Pure 1-(phenylsulfonyl)-3-phenyl-7-substituted-4,5-dioxo indoles were
obtained as amorphous solids.
3-Bromo-5-methoxyindole (8). The synthesis of compound 8
was carried out as previously described,54 and its analytical character-
ization conﬁrmed its structure.
1-Phenylsulfonyl-3-phenyl-5-methoxyindole (9a). The syn-
thesis of compound 9a was carried out as previously described,55 and
its analytical characterization conﬁrmed its structure.
1-Phenylsulfonyl-3-aryl-5-Substituted Indoles, General Suzuki
Procedure (9b,c, 12d,e). 1-Phenylsulfonyl-3-bromo-5-methoxy- (11)
or 5-hydroxy indole (13) (1 equiv) and an arylboronic acid (1.17 equiv)
were placed in a two-necked round-bottom ﬂask, equipped with a
CaCl2 valve. The ﬂask was ﬂushed with nitrogen to remove any trace
of oxygen. The middle neck was closed by a rubber septum, then dry
dimethoxyethane (DME, ≈0.07 M concentration in 11) and pre-
viously deareated aqueous 2 M K2CO3 (1.29 equiv) were added and
the resulting mixture was stirred at room temperature under nitro-
gen atmosphere. Finally, PdTetrakis (0.05 equiv) and previously
deareated EtOH (ﬁnal 4/1 DME/EtOH ratio) were added under nitro-
gen ﬂushing. A pale yellow solution was formed. The rubber septum was
removed, and then the main-middle neck was equipped with a con-
denser surmounted by a CaCl2 valve. The pale yellow solution was
stirred under nitrogen atmosphere, reﬂuxed for 8 h, and left to stir at
room temperature overnight. Then, the reaction mixture was diluted
with a saturated solution of NH4Cl (1 volume) and extracted with
EtOAc (1.5 volumes, three times). The organic phase were washed
with saturated aqueous NH4Cl (3 volumes) and with brine (3 volumes),
then dried over Na2SO4 and ﬁltered. The crude was puriﬁed by ﬂash
chromatography on silica gel, aﬀording pure 1-phenylsulfonyl-3-aryl-5-
substituted indoles as amorphous solids.
1-Arylsulfonyl-3-phenyl-5-methoxyindoles, General N-Aryl-
sulfonylation Procedure (9f−i). Aqueous 50% KOH (8 equiv) was
added to a stirred mixture of 3-phenyl-5-methoxy indole 14 (1 equiv)
and n-Bu4N
+HSO4
− (0.1 equiv) in CH2Cl2 (≈0.2 M concentration
in 14). The reaction was stirred vigorously at room temperature for
10 min. An arylsulfonyl chloride (1.7 equiv) in CH2Cl2 (total ≈0.1 M
concentration in 14) was then added, and the mixture turned to
orange-brown. The reaction was monitored by TLC (eluent: n-Hex/
EtOAc 9/1). After 3 h, the reaction was stopped by diluting with water
(1 volume) and extracting with CH2Cl2 (2 volumes, two times). The
collected organic layers were washed with water (2 volumes) and brine
(2 volumes), and dried over sodium sulfate. The solvent was evapo-
rated under reduced pressure aﬀording a crude. The crude was puriﬁed
through ﬂash chromatography on silica gel, aﬀording pure 1-arylsulfonyl-
3-phenyl-5-methoxy indoles as amorphous solids.
Figure 12. Scratch assay in PANC-1 and MDA-MB-231 cells. Images
of invaded cells at 0, 24, and 48 h after scratching and treatment with
DMSO (CTRL) or 6a were taken from a time-lapse sequence of cell
migration; wounds with consistent shape within each well were gen-
erated using a 200 μL tip. Residual open area at diﬀerent time points is
indicated as calculated by ImageJ software (*p < 0.05).
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1-Phenylsulfonyl-3-bromo-5-methoxyindole (11). The syn-
thesis of compound 11 was carried out as previously described,56 and
its analytical characterization conﬁrmed its structure.
1-Phenylsulfonyl-3-phenyl-5-hydroxyindole (12a). Initially,
1 M BBr3 in CH2Cl2(26.4 mL, 6 equiv) was slowly added under nitrogen
atmosphere and at −78 °C to a stirred solution of 1-phenylsulfonyl-3-
phenyl-5-methoxy indole 9a (1.6 g, 4.41 mmol, 1 equiv) in dry CH2Cl2
(22 mL, ≈0.2 M concentration). The temperature was slowly increased
to room temperature while monitoring by TLC (eluents: n-Hexane/
EtOAc 8/2). The resulting dark green solution was immediately diluted
with water (150 mL) and neutralized with saturated aqueous NaHCO3.
The reaction mixture was extracted with CH2Cl2 (3 × 150 mL). The
collected organic phases were then washed with brine (400 mL), dried
over Na2SO4, and ﬁltered. The solvent was removed under reduced
pressure. The crude (1.7 g) was puriﬁed by ﬂash chromatography on
silica gel, yielding pure compound 12a (1.34 g, 3.84 mmol, 87% yield)
as a white solid. 1H NMR (400 MHz, acetone d6): δ(ppm) 8.29
(s, 1H, OH), 8.05−8.03 (m, 2H, o-ArSO2), 7.93 (d, 1H, J = 8.9 Hz, H7),
7.84 (s, 1H, H2), 7.69−7.65 (m, 3H, p-ArSO2,o-Ar), 7.60−7.56
(m, 2H, m-ArSO2), 7.50−7.46 (m, 2H, m-Ar), 7.38 (tt, 1H, J = 7.4 Hz,
J = 1.2 Hz, p-Ar), 7.21 (d, 1H, J = 2.4 Hz, H4), 6.96 (dd, 1H, J = 8.9 Hz,
J = 2.4 Hz, H6). 13C NMR (75.4 MHz, acetone d6): δ(ppm) 155.5,
138.9, 135.1, 134.0, 131.4, 130.4, 129.8, 128.6, 128.4, 127.8, 124.9,
115.6, 115.0, 106.0. MS (ESI+): m/z 721.0 [2M+Na+]. Calculated MS,
C20H 15NO3S: 349.08.
1-Aryl/Alkylsulfonyl-3-Substituted-5-Hydroxyindoles, General
Demethylation Procedure (12a−c, 12f−i, 12k, 12l, 13). First, 1 M
BBr3 in CH2Cl2(6 equiv) was slowly added under nitrogen atmosphere
and at −78 °C to a stirred solution of 1-aryl/alkylsulfonyl-3-substituted-
5-methoxy indoles(1 equiv) in dry CH2Cl2 (≈0.2 M concentration).
The temperature was slowly increased to room temperature while
monitoring by TLC, then it was immediately diluted with water
(5 volumes) and neutralized with saturated aqueous NaHCO3. The
reaction mixture was extracted with CH2Cl2 (5 volumes, three times).
The collected organic phases were then washed with brine (15 volumes),
dried over Na2SO4, and ﬁltered. The solvent was removed under
reduced pressure. The crude hydroxyl indoles were puriﬁed by ﬂash
chromatography on silica gel, aﬀording pure 1-aryl/alkylsulfonyl-3-
substituted-5-hydroxy indoles as amorphous solids.
3-Phenyl-5-methoxyindole (14). Aqueous 3 M NaOH (21 mL,
63 mmol, 46 equiv) was added dropwise in 30 min to a solution of
1-phenysulfonyl-3-phenyl-5-methoxy indole 9a (500 mg, 1.38 mmol,
1 equiv) in 2/1 MeOH/THF (207 mL). The pale pink mixture was
warmed up to 80 °C. The reaction was monitored by TLC (eluant:
n-Hex/EtOAc 8/2). After 2 h the reaction was stopped by acidifying
with 3 N HCl (21 mL), and the organic solvents were evaporated under
reduced pressure. The aqueous residue was extracted with EtOAc
(3 × 100 mL). The collected organic layers were washed with brine
(450 mL), and dried over sodium sulfate. The solvent was evaporated
under reduced pressure aﬀording a crude brown oil (365 mg), that was
puriﬁed by ﬂash chromatography on silica gel (eluant: n-Hex/EtOAc
85/15). Pure compound 14 (300 mg, 1.34 mmol, 97% yield) was
obtained as a pale yellow solid. 1H NMR (400 MHz, acetone d6):
δ(ppm) 10.33 (1H, bs, NH), 7.72−7.69 (2H, m, o-Ar), 7.58 (1H, d,
J = 2.6 Hz, H2), 7.47−7.36 (4H, m, H4, H7, m-Ar), 7.26−7.21 (1H, m,
p-Ar), 6.85 (1H, dd, J = 2.50 Hz, J = 8.80 Hz, H6), 3.84 (3H, s, OMe).
MS (ESI+): m/z 748.9 [2M+Na+]. Calculated MS, C15H13NO: 223.27.
Biology. Ampliﬁed Luminescent Proximity Homogeneous Assay
(ALPHA Screen). AlphaScreen assays have been performed using
histidine (nickel) chelate detection kit (PerkinElmer, 6760619), based
on the reaction of an His-tagged HuR protein and a biotinylated single
strand RNA (BITEG-RNA), as previously described.28 The full-length
HuR recombinant protein has been expressed in E. coli Rosetta DH5α
according to an already published protocol.27 Hooking point curves,
with 50 nM of BITEG-RNA probe, have been performed to test its acti-
vity after puriﬁcation and dialysis. Dissociation equilibrium constants (Ki)
were calculated with respect to a KD of 2.5 nM for the Bi−AU ligand
interaction, in the presence of as low as 0.5% DMSO (relative control)
and of tanshinone mimics. Non speciﬁc interference with the assay has
been evaluated by reacting the same amount of acceptor and donor
beads (20 μg/mL/well) with biotinylated-His6 molecule in the same
experimental conditions. GraphPad Prism software v5.1 has been used
for ﬁtting calculation and statistical signiﬁcance. rHuR expressed in
HEK293T has been puriﬁed according to a previously published
protocol.27
RNA-Electrophoretic Mobility Shift Assays (REMSAs). REMSAs were
performed as previously indicated,27 with minor modiﬁcations. Besides
recombinant full-length HuR, HuR RRM1−2 and RRM3 constructs
were used to express and purify proteins as previously described.27,29
At least 10-fold excess of recombinant HuR and its RRMs were
incubated for 30 min with either 75 fmol of 5′-DY681-labeled AU-rich
RNA probe or with 25 nM of 5′-FAM-labeled RNA probe or with 500 nM
of Cy-3-RNA probe and DMSO as control or tanshinone mimics at their
reference doses. Then samples were loaded on 4% native polyacryl-
amide gel, image was developed with Odyssey infrared Imaging System
(LI-COR Biosciences) for DY681-labeled RNA or in Typhoon Trio
scanner (GE Healthcare) at high resolution for FAM and Cy-3 probe.
Dynamic Mass Redistribution (DMR). The EnSight Multimode
Plate Reader (PerkinElmer) was used to perform DMR analyses. Full-
length HuR protein (15 μL/well of a 50 μg/mL HuR solution in
20 mM sodium acetate buﬀer, pH 5.5) was immobilized on label-free
microplate (EnSpire-LFB high sensitivity microplates) by amine-
coupling chemistry, incubating the microplate o/n at 4 °C. Impor-
tantly, each well contains a reactive area, containing chemical groups to
allow amine coupling reaction, and empty area. After the initial step of
immobilization, the unbound protein was washed away and the plate
equilibrated using the assay buﬀer (HEPES 25 mM pH 8, 3 mM
MgCl2, 100 mMNaCl, 8% Glycerol, 0.05% BSA, 0.005% Tween20).
Next, the interaction between tanshinone mimics, diluted to diﬀerent
concentrations in the same buﬀer, and HuR protein was monitored
during 30 min at room temperature. The EnSight software (Kaleido)
acquires data by automatically subtracting the signal in the empty area
from the one of the reactive area. Binding response is then calculated
by subtracting the baseline read from the ﬁnal read. This dual-control
strategy guarantees that nonspeciﬁc signals arising from the potential
interaction of the HuR protein with the surface of the plate are already
subtracted in each well. All the steps were executed by employing a
Zephyr Compact Liquid Handling Workstation. The Kaleido software
was used to acquire and process the data.
Circular Dichroism Experiments. All experiments has been done by
using a ﬁnal 10 μM concentration of TNF-ARE and 10 μM 6a, 10 mM
in sodium phosphate buﬀer pH 7.3. CD spectra were measured in
a JASCO-700 Spectrophotometer at 240−350 nm range (DMSO
interfered below 240 nm), at 100 nm/min speed. Next 10 μM
6a dissolved in sodium phosphate buﬀer pH 7.3 was also measured sepa-
rately to exclude background from the 6a (10 μM) + TNF ARE (10 μM)
spectra. The analyzed spectra Δε was then plotted using the Graphpad
Prism 6 plotting tool.
Cell Culture. Human breast adenocarcinoma MCF7 (ICLC;
HTL95021) and MDA-MB-231 (ICLC; HTL99004) and pancreatic car-
cinoma PANC-1 (kindly provided by G. Feldmann)57 cell lines were
cultured in high glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS, Lonza), 2 mM
L-glutamine, 100 U/ml penicillin-streptomycin (Lonza) in standard
growth conditions.
RIP and qRT-PCR. Five million MCF7 cells/sample were used for
each RIP experiment, performed as previously described,58 without
cross-linking steps and using 1 μg/mL of anti-HuR antibody (Santa
Cruz, 71290) or of mouse IgG isotype (negative control, Santa Cruz
2025). TRIzol reagent was added directly to the beads for HuR-bound
RNA isolation and processed for qRT-PCR analysis. Quantitative
PCRs, after cDNA Synthesis (Thermo Scientiﬁc, K1612) were
performed using Universal SYBR Master Mix (KAPA Biosystems,
KR0389) on CFX-96/384 thermal cyclers (BIO-RAD), as previously
described.27 Fold enrichment was determined using the eq 2-ΔΔCt,
where the Ct value for HuR and IgG IP was subtracted from the Ct
value of the housekeeping gene RPLP0 to yield the ΔCt value. For
each condition, ΔCt value for the HuR and IgG IP sample were
calculated in triplicate. The delta Ct value for HuR in the IgG IP
samples were calculated in the same way. Then delta−delta Ct values
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were calculated from the diﬀerence between HuR IP samples and IgG
IP samples. Total expression level of the diﬀerent mRNAs was assessed
by extracting total RNA from the control and treated samples and then
qRT-PCRs have been performed as described previously. The
sequence of the primer used for each PCR are the following:
gene primer sequence
FW 5′-3′
primer sequence
RV 5′-3′
RPLP0 CATTCTCGCTT-
CCTGGAG
CTTGACCTTTTCAGC-
AAGTGG
ERBB2 GGTACTGAAAG-
CCTTAGGGAAGC
ACACCATTGCTGTTC-
CTTCCTC
VEGFA CCGCAGACGTG-
TAAATGTTCCT
CGGCTTGTCACATCT-
GCAAGTA
CTNNB1 GACCTCATGGA-
TGGGCTGCCT
GATTTACAAATAGCC-
TAAACCAC
RNA18s GCAGCTAGGAA-
TAATGGAATAG
TGGCAAATGCTTTCG-
CTCTG
HPRT1 TGACACTGGCA-
AAACAATGCA
GGTCCTTTTCACCAG-
CAAGCT
Immunoﬂuorescence Experiments. 8.000 MCF7 cells/well were
seeded in a 96-well plate and treated with 1 μM of 1, or 10 μM of
tanshinone mimics, or 2.5 μM of ActD (Sigma A1410) for 3 h and
were ﬁxed with 3.7% paraformaldehyde (PFA) for 15 min at RT. Cells
were treated for 10 min with permeabilization buﬀer (200 mM sucrose,
0.2% Triton X-100) followed by blocking for 15 min with blocking
buﬀer (2% Bovine Serum Albumin in PBS). Primary antibody anti-
HuR 1:250 in 3% BSA and secondary ﬂuorophore conjugated (Alexa
594 Red) antibody (1:500) were diluted in PBS + BSA 0.6%. DAPI
Blue (1.5 μg/mL) in PBS + BSA 0.6% was used to detect nuclei.
PerkinElmer image plate reader Operetta was used for image acquisition
and evaluation by selecting 13 ﬁelds/well. The ratio between nuclear
and cytoplasmic signal represents the mean of single cells for every well.
Cell Viability Assay. To test cell viability, cells were grown and
treated in 96 well-plate for 48 h. Cells were then assayed using OZBlue
Cell Viability kit (Oz Biosciences, BL000). In brief, OZBlue was added
at 10% volume of culture media to each well and cells were further incu-
bated for 3 h at 37 °C. Fluorescence was then determined (excitation
560 and emission 590 nm) by a Tecan microplate reader. Cell survival
was calculated with respect to control (DMSO), and IC50 values were
determined by ﬁtting with GraphPad Prism software v5.1.
Cell Migration Assay. Cells were seeded for migration assay and
treated with tanshinone mimics as previously described.59 Images of the
same ﬁeld were acquired immediately (t = 0), after 24 and 48 h using a
Leica DM IL Led microscope (5× magniﬁcation) and wounded-open
areas were measured using ImageJ software.
Statistical Analysis. All data are expressed as means ± SD from at
least two independent experiments. Magnitude of signiﬁcance was eval-
uated by student t test and probability (P) values <0.05, < 0.01, and
<0.001 were indicated with *, **, *** symbols, respectively.
In Silico Pan Assay Interference, NMR, and Molecular
Modeling studies. In Silico Pan Assay Interference. All compounds
as reported in Table 1 were screened for Pan Assay Interference using
the PAINS-Remover Web server (http://www.cbligand.org). All com-
pounds passed this ﬁltering.
NMR Measurements on Protein/Compound 6a Interaction. The
assignment of RRM1-RRM2 tandem domains of HuR was previously
reported (BMRB code: 27002).50 The eﬀect of the tanshinone mimic
6a on the RRM1-RRM2 tandem domains of HuR (100 μM) has been
evaluated in the following experimental conditions: 20 mMTris-Cl, pH 8,
10 mM Gly, 50 mM NaCl. 2D 1H 15N HSQC spectra were acquired at
298 K on Bruker Avance 900 MHz NMR spectrometer to monitor the
eﬀect of increasing amounts of the ligand (HuR/compound 6a molar
ratio of 1:0.2, 1:0.4, 1:0.6, 1:0.8, 1:1, 1:2) added to the protein solution.
Docking Calculations. Molecular docking was carried out using the
Glide 6.560 and the AutoDock 4.261 software. 6a three-dimensional struc-
ture was ﬁrst generated and subsequently prepared through the LigPrep
module, as implemented in the Maestro 10.0.013 graphical user inter-
face.62 As experimental results suggest that (I) HuR cannot bind both
6a and RNA at the same time and that (II) 6a stabilizes HuR in a
“closed” conformation, we selected as receptor structure for docking calcu-
lations the structure of the HuR−mRNA complex (PDB ID: 4ED5),49
and removed the RNA strand. Indeed this structure was not only the
HuR highest resolution structure available but also the best represen-
tative structure of a HuR “closed” form available. Receptor structure
was then prepared through the Protein Preparation Wizard, also imple-
mented in Maestro, and the OPLS-2005 force ﬁeld. Water molecules
and residual crystallographic buﬀer components were removed, missing
side chains were built using the Prime module, hydrogen atoms were
added, side chains protonation states at pH 7.0 were assigned and,
ﬁnally, minimization was performed until the RMSD of all the heavy
atoms was within 0.3 Å of the crystallographically determined positions.
In both cases, the binding pocket was identiﬁed by placing a cube
centered in proximity of the “hinge” loop between the RRM1 and
RRM2 domains. Docking calculations were performed as following.
Docking with Glide was carried out in extra-precision (XP) mode, using
GlideScore for ligand ranking. The inner box size was chosen to be 40 Å
in all directions and the size of the outer box was set by choosing a
threshold length for the ligand size to be docked of 30 Å. A maximum of
100 000 poses per ligand was set to pass to the grid reﬁnement calcu-
lation, and the best 10 000 poses were kept for the energy minimization
step. The maximum number of poses per ligand to be outputted was set
to 10. In the case of docking with Autodock, the ligand and receptor
structures were ﬁrst converted to AD4 format ﬁles, adopting the
Gesteiger-Marsili partial charges, via AutoDockTools.61 The box size
was set to have 117 × 125 × 127 points in the three-dimensional space
with a Grid spacing of 0.481 Å per point using AutoGrid 4.2. A hundred
independent runs of the Lamarckian genetic algorithm local search
(GALS) method per docking calculation were performed, by applying
a threshold of maximum 10 million energy evaluations per run. The rest
of the docking parameters was set as default. Docking conformations
were clustered on the basis of their RMSD (tolerance = 2.0 Å) and
were ranked according to the AutoDock scoring function. In both
cases, the box size was chosen so as to encompass the whole RNA
binding surface of HuR.
Molecular Dynamics Simulations and Analyses. The best
ranked HuR−6a complexes, as issuing from the docking calculations,
were submitted to MD simulations with NAMD,63 using the ﬀ99SBildn
Amber force ﬁeld parameters,64,65 for protein and the parameters
recently developed by Allneŕ and co-workers for ions.66 Parameters for
6a were generated in two steps. Initially, charges were computed using
the restrained electrostatic potential (RESP) ﬁtting procedure.67 The
ESP was ﬁrst calculated by means of the Gaussian09 package68 using a
6-31G* basis set at Hartree−Fock level of theory, and then the RESP
charges were obtained by a two-stages ﬁtting procedure using the
program RED.69,70 Missing bond, angle, torsion, and improper torsion
angle parameters were then generated using Antechamber.71 The
complex was then solvated in a 15 Å layer cubic water box using the
TIP3P water model parameters. Neutrality was reached by adding ﬁve
further Cl− ions. The ﬁnal system size was ∼75 Å × 74 Å × 93 Å for a
total number of atoms of ∼48 000. A 10 Å cutoﬀ (switched at 8.0 Å)
was used for atom pair interactions. The long-range electrostatic inter-
actions were computed by means of the particle mesh Ewald (PME)
method using a 1.0 Å grid spacing in periodic boundary conditions.
The RATTLE algorithm was applied to constrain bonds involving
hydrogen atoms, and thus a 2 fs integration time step could be used.
The system was minimized in two stages: ﬁrst, a 20 000-step run was
carried out with restraints on all the protein and ligand atoms (5 kcal/
mol/Å2); then, a further 10 000-step minimization was carried out by
applying restraints on the ligand and Cα protein atoms only. A 2 ns
NPT simulation at 200 K and 1 atm was performed with restraints on
all the protein atoms (5 kcal/mol/Å2), to adjust the volume of the
simulation box, while preserving the minimized protein structure
obtained in the previous steps. Afterward, the system was slowly
heated up to 300 K over a 3 ns period, gradually releasing the restraints
(on the ligand and protein Cα atoms only) to 1 kcal/mol/Å
2 along the
thermalization process. Subsequently, the system was equilibrated for
2 ns, gradually reducing the restraints to zero. Production runs were
then performed under NPT conditions at 1 atm and 300 K. Each
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of the four simulations was extended up to 1.5 μs. MD trajectory
visualization and RMSD analysis were performed by means of the
VMD software.72 All other analyses were performed using CPPTRAJ73
or in-house scripts exploiting the MDAnalysis library.74 For analysis
purposes, trajectories were ﬁtted onto the β-sheet backbone atoms,
owing to the HuR high overall ﬂexibility, using the ﬁrst frame as
reference and then one frame each 100 ps. In the speciﬁc case of
contact analysis only, we employed a diﬀerent reference structure.
Indeed, as the aim of the analysis was also to discriminate between
contacts established in the HuR mRNA-bound conformation and
possible contacts characteristic of new 6a-induced conformations, we
made a distinction between native and non-native contacts. A non-
native contact, contrarily to a native contact, is a contact between
atoms within a convenient distance (here 4 Å) that is not present in a
certain reference structure (here the structure used for the docking
calculations). Figures were generated using the UCSF-Chimera
software package75 or in-house scripts with Matplotlib.76
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